汇宇制药：自愿披露注射用HY0001aI期临床试验首例受试者给药的公告

Group 1 - The core point of the article is that Huayu Pharmaceutical announced that its wholly-owned subsidiary, Sichuan Huayu Haiyue Pharmaceutical Technology Co., Ltd., has initiated a Phase I clinical trial for its innovative biological drug HY0001a, aimed at treating advanced solid tumors, with the first patient successfully dosed recently [2] Group 2 - The drug HY0001a is classified as a first-class innovative biological drug, indicating its potential significance in the pharmaceutical market [2] - The commencement of the clinical trial marks a critical milestone in the drug development process, reflecting the company's commitment to advancing cancer treatment options [2]